Which has preferable valuation and earnings, JSPR or AARD?

Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jasper Therapeutics N/A N/A -$75.80M -$3.23 N/A Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A

Is JSPR or AARD more profitable?

Aardvark Therapeutics' return on equity of -61.71% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -613.51% -162.52% Aardvark Therapeutics N/A -61.71% -56.29%

Does the media favor JSPR or AARD?

In the previous week, Aardvark Therapeutics had 3 more articles in the media than Jasper Therapeutics. MarketBeat recorded 6 mentions for Aardvark Therapeutics and 3 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.94 beat Aardvark Therapeutics' score of 0.60 indicating that Jasper Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aardvark Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, JSPR or PMN?

Promis Neurosciences is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jasper Therapeutics N/A N/A -$75.80M -$3.23 N/A Promis Neurosciences N/A N/A -$39.72M -$14.51 N/A

Is JSPR or PMN more profitable?

Promis Neurosciences' return on equity of -237.99% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -613.51% -162.52% Promis Neurosciences N/A -237.99% -151.04%

Does the media prefer JSPR or PMN?

In the previous week, Jasper Therapeutics and Jasper Therapeutics both had 3 articles in the media. Jasper Therapeutics' average media sentiment score of 0.94 beat Promis Neurosciences' score of 0.63 indicating that Jasper Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Promis Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is QTTB or JSPR more profitable?

Q32 Bio's return on equity of 149.23% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 149.23% 34.50% Jasper Therapeutics N/A -613.51% -162.52%

Does the media favor QTTB or JSPR?

In the previous week, Q32 Bio had 7 more articles in the media than Jasper Therapeutics. MarketBeat recorded 10 mentions for Q32 Bio and 3 mentions for Jasper Therapeutics. Q32 Bio's average media sentiment score of 1.20 beat Jasper Therapeutics' score of 0.94 indicating that Q32 Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Q32 Bio 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, JSPR or LONA?

Athira Pharma is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jasper Therapeutics N/A N/A -$75.80M -$3.23 N/A Athira Pharma N/A N/A -$105.61M -$5.21 N/A

Is JSPR or LONA more profitable?

Athira Pharma's return on equity of -381.01% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -613.51% -162.52% Athira Pharma N/A -381.01% -225.74%

Which has higher valuation and earnings, JSPR or ONCY?

Oncolytics Biotech is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jasper Therapeutics N/A N/A -$75.80M -$3.23 N/A Oncolytics Biotech N/A N/A -$28.76M -$0.31 N/A

Is JSPR or ONCY more profitable?

Jasper Therapeutics' return on equity of -613.51% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -613.51% -162.52% Oncolytics Biotech N/A -2,185.97% -321.54%

Does the media prefer JSPR or ONCY?

In the previous week, Oncolytics Biotech had 12 more articles in the media than Jasper Therapeutics. MarketBeat recorded 15 mentions for Oncolytics Biotech and 3 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.94 beat Oncolytics Biotech's score of -0.53 indicating that Jasper Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncolytics Biotech 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Jasper Therapeutics (JSPR) Competitors

$0.50 -0.05 (-8.94%)

As of 12:27 PM Eastern

Compare

JSPR vs. AARD, PMN, QTTB, LONA, and ONCY

Should you buy Jasper Therapeutics stock or one of its competitors? MarketBeat compares Jasper Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jasper Therapeutics include Aardvark Therapeutics (AARD), Promis Neurosciences (PMN), Q32 Bio (QTTB), Athira Pharma (LONA), and Oncolytics Biotech (ONCY). These companies are all part of the "pharmaceutical products" industry.

How does Jasper Therapeutics compare to Aardvark Therapeutics?

Jasper Therapeutics (NASDAQ:JSPR) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Jasper Therapeutics has a beta of 3.01, suggesting that its share price is 201% more volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 4.5, suggesting that its share price is 350% more volatile than the broader market.

Jasper Therapeutics presently has a consensus target price of $13.14, indicating a potential upside of 2,418.27%. Aardvark Therapeutics has a consensus target price of $19.70, indicating a potential upside of 421.16%. Given Jasper Therapeutics' higher probable upside, equities research analysts plainly believe Jasper Therapeutics is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46

Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

In the previous week, Aardvark Therapeutics had 3 more articles in the media than Jasper Therapeutics. MarketBeat recorded 6 mentions for Aardvark Therapeutics and 3 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.94 beat Aardvark Therapeutics' score of 0.60 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aardvark Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aardvark Therapeutics' return on equity of -61.71% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-613.51%	-162.52%
Aardvark Therapeutics	N/A	-61.71%	-56.29%

79.8% of Jasper Therapeutics shares are held by institutional investors. 4.6% of Jasper Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Aardvark Therapeutics beats Jasper Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Jasper Therapeutics compare to Promis Neurosciences?

Jasper Therapeutics (NASDAQ:JSPR) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

Jasper Therapeutics has a beta of 3.01, suggesting that its stock price is 201% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.19, suggesting that its stock price is 119% less volatile than the broader market.

79.8% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 4.6% of Jasper Therapeutics shares are held by company insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Jasper Therapeutics currently has a consensus target price of $13.14, indicating a potential upside of 2,418.27%. Promis Neurosciences has a consensus target price of $26.50, indicating a potential upside of 172.35%. Given Jasper Therapeutics' higher possible upside, analysts plainly believe Jasper Therapeutics is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Promis Neurosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Promis Neurosciences' return on equity of -237.99% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-613.51%	-162.52%
Promis Neurosciences	N/A	-237.99%	-151.04%

Promis Neurosciences is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

In the previous week, Jasper Therapeutics and Jasper Therapeutics both had 3 articles in the media. Jasper Therapeutics' average media sentiment score of 0.94 beat Promis Neurosciences' score of 0.63 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Promis Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Jasper Therapeutics beats Promis Neurosciences on 8 of the 13 factors compared between the two stocks.

How does Jasper Therapeutics compare to Q32 Bio?

Q32 Bio (NASDAQ:QTTB) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 79.8% of Jasper Therapeutics shares are held by institutional investors. 40.0% of Q32 Bio shares are held by insiders. Comparatively, 4.6% of Jasper Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Q32 Bio's return on equity of 149.23% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	149.23%	34.50%
Jasper Therapeutics	N/A	-613.51%	-162.52%

Q32 Bio has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.01, meaning that its stock price is 201% more volatile than the broader market.

Q32 Bio presently has a consensus price target of $13.50, indicating a potential upside of 14.31%. Jasper Therapeutics has a consensus price target of $13.14, indicating a potential upside of 2,418.27%. Given Jasper Therapeutics' higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Jasper Therapeutics	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Q32 Bio has higher revenue and earnings than Jasper Therapeutics. Jasper Therapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	3.73	$29.82M	$2.66	4.44
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A

In the previous week, Q32 Bio had 7 more articles in the media than Jasper Therapeutics. MarketBeat recorded 10 mentions for Q32 Bio and 3 mentions for Jasper Therapeutics. Q32 Bio's average media sentiment score of 1.20 beat Jasper Therapeutics' score of 0.94 indicating that Q32 Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Q32 Bio	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Q32 Bio beats Jasper Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Jasper Therapeutics compare to Athira Pharma?

Jasper Therapeutics (NASDAQ:JSPR) and Athira Pharma (NASDAQ:LONA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Jasper Therapeutics presently has a consensus price target of $13.14, indicating a potential upside of 2,418.27%. Athira Pharma has a consensus price target of $15.00, indicating a potential upside of 71.43%. Given Jasper Therapeutics' higher probable upside, equities research analysts clearly believe Jasper Therapeutics is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Jasper Therapeutics had 2 more articles in the media than Athira Pharma. MarketBeat recorded 3 mentions for Jasper Therapeutics and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.96 beat Jasper Therapeutics' score of 0.94 indicating that Athira Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Jasper Therapeutics	Positive
Athira Pharma	Positive

79.8% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 4.6% of Jasper Therapeutics shares are owned by company insiders. Comparatively, 25.7% of Athira Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Athira Pharma is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A

Jasper Therapeutics has a beta of 3.01, indicating that its share price is 201% more volatile than the broader market. Comparatively, Athira Pharma has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market.

Athira Pharma's return on equity of -381.01% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-613.51%	-162.52%
Athira Pharma	N/A	-381.01%	-225.74%

Summary

Jasper Therapeutics beats Athira Pharma on 9 of the 13 factors compared between the two stocks.

How does Jasper Therapeutics compare to Oncolytics Biotech?

Jasper Therapeutics (NASDAQ:JSPR) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

79.8% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 4.6% of Jasper Therapeutics shares are held by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Jasper Therapeutics' return on equity of -613.51% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-613.51%	-162.52%
Oncolytics Biotech	N/A	-2,185.97%	-321.54%

Jasper Therapeutics has a beta of 3.01, meaning that its share price is 201% more volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

In the previous week, Oncolytics Biotech had 12 more articles in the media than Jasper Therapeutics. MarketBeat recorded 15 mentions for Oncolytics Biotech and 3 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.94 beat Oncolytics Biotech's score of -0.53 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncolytics Biotech	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Jasper Therapeutics currently has a consensus target price of $13.14, indicating a potential upside of 2,418.27%. Oncolytics Biotech has a consensus target price of $8.50, indicating a potential upside of 824.11%. Given Jasper Therapeutics' higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than Oncolytics Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Oncolytics Biotech is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

Summary

Jasper Therapeutics beats Oncolytics Biotech on 9 of the 14 factors compared between the two stocks.

Get Jasper Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JSPR vs. The Competition

Export

Metric	Jasper Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.61M	$3.26B	$6.26B	$12.44B
Dividend Yield	N/A	2.33%	2.69%	5.30%
P/E Ratio	-0.16	17.75	22.35	24.23
Price / Sales	N/A	323.71	555.60	126.08
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	3.48	6.55	9.82	6.73
Net Income	-$75.80M	$24.20M	$3.56B	$336.97M
7 Day Performance	-42.17%	-3.25%	-1.16%	0.79%
1 Month Performance	-43.90%	0.48%	3.85%	5.38%
1 Year Performance	-91.15%	47.06%	27.33%	34.55%

Jasper Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JSPR Jasper Therapeutics	3.106 of 5 stars	$0.50 -8.9%	$13.14 +2,518.1%	-89.9%	$14.05M	N/A	N/A	20	News Coverage
AARD Aardvark Therapeutics	4.3269 of 5 stars	$4.54 flat	$19.70 +333.9%	-64.3%	$99.04M	N/A	N/A	18
PMN Promis Neurosciences	3.1379 of 5 stars	$10.98 flat	$26.50 +141.3%	-15.2%	$98.47M	N/A	N/A	5	Analyst Upgrade
QTTB Q32 Bio	4.6231 of 5 stars	$5.80 flat	$13.50 +132.8%	+590.7%	$98.34M	$53.74M	2.18	39	News Coverage Positive News Insider Trade High Trading Volume
LONA Athira Pharma	3.0657 of 5 stars	$10.33 flat	$10.00 -3.2%	N/A	$97.03M	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JSPR) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jasper Therapeutics (JSPR) Competitors

JSPR vs. AARD, PMN, QTTB, LONA, and ONCY

How does Jasper Therapeutics compare to Aardvark Therapeutics?

Summary

How does Jasper Therapeutics compare to Promis Neurosciences?

Summary

How does Jasper Therapeutics compare to Q32 Bio?

Summary

How does Jasper Therapeutics compare to Athira Pharma?

Summary

How does Jasper Therapeutics compare to Oncolytics Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR vs. The Competition

Jasper Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jasper Therapeutics (JSPR) Competitors

JSPR vs. AARD, PMN, QTTB, LONA, and ONCY

How does Jasper Therapeutics compare to Aardvark Therapeutics?

Which has more volatility and risk, JSPR or AARD?

Do analysts recommend JSPR or AARD?

Which has preferable valuation and earnings, JSPR or AARD?

Does the media favor JSPR or AARD?

Is JSPR or AARD more profitable?

Do insiders & institutionals believe in JSPR or AARD?

Summary

How does Jasper Therapeutics compare to Promis Neurosciences?

Which has more risk & volatility, JSPR or PMN?

Do insiders & institutionals believe in JSPR or PMN?

Do analysts rate JSPR or PMN?

Is JSPR or PMN more profitable?

Which has higher earnings & valuation, JSPR or PMN?

Does the media prefer JSPR or PMN?

Summary

How does Jasper Therapeutics compare to Q32 Bio?

Do institutionals and insiders believe in QTTB or JSPR?

Is QTTB or JSPR more profitable?

Which has more risk & volatility, QTTB or JSPR?

Do analysts recommend QTTB or JSPR?

Which has better earnings and valuation, QTTB or JSPR?

Does the media favor QTTB or JSPR?

Summary

How does Jasper Therapeutics compare to Athira Pharma?

Do analysts prefer JSPR or LONA?

Does the media refer more to JSPR or LONA?

Do insiders & institutionals have more ownership in JSPR or LONA?

Which has preferable valuation & earnings, JSPR or LONA?

Which has more volatility and risk, JSPR or LONA?

Is JSPR or LONA more profitable?

Summary

How does Jasper Therapeutics compare to Oncolytics Biotech?

Do insiders and institutionals hold more shares of JSPR or ONCY?

Is JSPR or ONCY more profitable?

Which has more volatility and risk, JSPR or ONCY?

Does the media prefer JSPR or ONCY?

Do analysts recommend JSPR or ONCY?

Which has higher valuation and earnings, JSPR or ONCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR vs. The Competition

Jasper Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools